Spoken Alpha
ABEONA THERAPEUTICS INC.
Abeona Therapeutics develops cell and gene therapies for rare genetic diseases. The company commercializes ZEVASKYN®, an FDA-approved autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa wounds, manufactured at its Cleveland facility and administered through a network of qualified treatment centers.
ABEONA THERAPEUTICS INC is a Healthcare company operating in Biotechnology with a $312.9M market cap.
ABEO missed consensus EPS by 0.5% in Q2 FY2026, reported Aug 12, 2026.
15 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ABEO.
$ curl https://api.spokenalpha.com/v1/companies/ABEOFAQ
Spoken Alpha indexes ABEO's earnings call transcripts at https://spokenalpha.com/companies/ABEO. Each call links to attributed speakers and parsed analyst Q&A. ABEONA THERAPEUTICS INC.'s own investor relations page is at https://investors.abeonatherapeutics.com/.
ABEONA THERAPEUTICS INC. (ABEO) held its most recent earnings call on 2026-08-13, covering fiscal Q2 2026.
ABEONA THERAPEUTICS INC. (ABEO) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-12 | $-0.35 | $-0.23 | -52.2% | $11.4M | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $-0.30 | $-0.39 | +23.1% | $8.7M | — | — | EODHD |
| Q4 FY2025 | 2026-03-22 | $-0.37 | $-0.33 | -9.4% | $5.4M | — | — | EODHD |
| Q3 FY2025 | 2025-11-11 | $-0.11 | $-0.34 | +67.7% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.47 | $-0.39 | -20.5% | $400.0K | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-0.24 | $-0.35 | +31.4% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-16 | $-0.32 | $-0.34 | +8.0% | $4.8M | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-0.63 | $-0.39 | -61.5% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-0.44 | $-0.34 | -29.4% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-14 | $-0.52 | $-0.53 | +1.9% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-17 | $-0.77 | $-0.47 | -63.8% | $2.8M | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.43 | $-0.54 | +20.4% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.50 | $-0.70 | +28.6% | $3.5M | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.67 | $-0.58 | -15.5% | $68.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-28 | $1.53 | $-0.75 | +100.0% | $68.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-1.48 | $-1.75 | +15.4% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-2.08 | $-0.67 | -100.0% | $1.0M | — | — | EODHD |
| Q1 FY2022 | 2022-05-12 | $-3.50 | $-3.25 | -7.7% | $346.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-3.50 | $-3.67 | +4.6% | $3.0M | — | — | EODHD |
| Q3 FY2021 | 2021-11-14 | $-3.52 | $-4.06 | +13.3% | $0 | — | — | EODHD |
Source: EODHD. ABEO reported actuals as published; sparse fields render as —.